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Abstract: OBJECTIVE: Dilutional hyponatremia is a serious adverse effect of desmopressin, a vaso-
pressin analog that is widely prescribed to manage monosymptomatic enuresis. The presentation of
hyponatremia, largely related to cerebral dysfunction, can include severe signs like altered mental status
and seizures. METHODS: We reviewed the literature dealing with altered mental status or seizures
in enuretic subjects on desmopressin. The retained publications included patients who were described
individually, revealing data on mode of administration, further identifiable factors predisposing to hy-
ponatremia, presentation and clinical course. RESULTS: We found 54 cases of hyponatremia secondary
to desmopressin treatment presenting with altered mental status or seizures. In most cases the compli-
cation developed 14 days or less after starting desmopressin. An intranasal formulation had been used in
47 patients. Excess fluid intake was documented as a contributing factor in at least 22 cases. In 6 cases
severe signs of hyponatremia developed in the context of intercurrent illnesses. CONCLUSION: Altered
mental status or seizures are very rare but recognized complications of desmopressin in enuresis. This
complication mostly develops in subjects managed with the intranasal formulation 14 days or less after
starting the medication, following excess fluid intake and during intercurrent illnesses.
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Abstract	  
Objective:	  Dilutional	  hyponatremia	  is	  a	  serious	  adverse	  effect	  of	  
desmopressin,	  a	  vasopressin	  analog	  that	  is	  widely	  prescribed	  to	  manage	  
enuresis.	  The	  presentation	  of	  hyponatremia,	  largely	  related	  to	  cerebral	  
dysfunction,	  can	  include	  severe	  signs	  like	  altered	  mental	  status	  and	  
seizures.	  
Methods:	  We	  reviewed	  the	  literature	  dealing	  with	  altered	  mental	  status	  or	  
seizures	  in	  enuretic	  subjects	  on	  desmopressin.	  The	  retained	  publications	  
included	  patients	  who	  were	  described	  individually,	  revealing	  data	  on	  mode	  of	  
administration,	  further	  identifiable	  factors	  predisposing	  to	  hyponatremia,	  
presentation	  and	  clinical	  course.	  
Results:	  We	  found	  54	  cases	  of	  hyponatremia	  secondary	  to	  desmopressin	  
treatment	  presenting	  with	  altered	  mental	  status	  or	  seizures.	  In	  most	  cases	  
the	  complication	  developed	  14	  days	  or	  less	  after	  starting	  desmopressin.	  An	  
intranasal	  formulation	  had	  been	  used	  in	  47	  patients.	  Excess	  fluid	  intake	  was	  
documented	  as	  a	  contributing	  factor	  in	  at	  least	  22	  cases.	  In	  6	  cases	  severe	  
signs	  of	  hyponatremia	  developed	  in	  the	  context	  of	  intercurrent	  illnesses.	  
Conclusion:	  Altered	  mental	  status	  or	  seizures	  are	  very	  rare	  but	  recognized	  
complications	  of	  desmopressin	  in	  enuresis.	  This	  complication	  mostly	  develops	  
in	  subjects	  managed	  with	  the	  intranasal	  formulation	  14	  days	  or	  less	  after	  









	   Enuresis,	  the	  involuntary	  release	  of	  urine	  by	  night	  in	  the	  absence	  of	  
defects	  of	  the	  nervous	  system	  or	  urinary	  tract,	  is	  common	  among	  school-­‐age	  
children	  and	  adolescents	  [1-­‐4].	  For	  this	  condition	  the	  vasopressin	  analog	  
desmopressin	  acetate	  (1-­‐deamino-­‐8-­‐D-­‐arginine	  vasopressin,	  often	  abbreviated	  
DDAVP)	  is	  widely	  prescribed	  and	  well	  tolerated.	  The	  dose	  of	  desmopressin,	  
which	  is	  administered	  either	  intranasally	  (since	  approximately	  1980)	  or	  
orally	  (since	  approximately	  1990)	  30-­‐60	  minutes	  before	  bedtime,	  is	  titrated	  
to	  best	  effect	  and	  the	  antienuretic	  efficacy	  is	  seen	  without	  delay	  once	  the	  
effect	  is	  reached	  [1-­‐4].	  
	   The	  most	  serious	  adverse	  effect	  of	  desmopressin	  is	  dilutional	  
hyponatremia.	  To	  prevent	  hyponatremia,	  fluid	  intake	  is	  limited	  from	  one	  hour	  
before	  to	  eight	  hours	  after	  administration	  of	  desmopressin	  [1-­‐4].	  
Furthermore,	  desmopressin	  is	  interrupted	  during	  intercurrent	  illnesses	  that	  
predispose	  to	  fluid	  or	  electrolyte	  imbalance	  such	  as	  fever,	  vomiting	  or	  
diarrhea	  [1-­‐4].	  The	  manifestations	  of	  hyponatremia	  are	  largely	  related	  to	  
dysfunction	  of	  the	  central	  nervous	  system	  and	  are	  more	  conspicuous	  when	  the	  
decrease	  in	  the	  sodium	  concentration	  is	  large	  or	  rapid.	  Headache,	  nausea	  or	  
vomiting	  are	  the	  most	  common	  presentation.	  More	  rarely,	  severe	  signs	  like	  
lethargy,	  restlessness,	  disorientation	  and	  epileptic	  seizures	  can	  be	  
observed.	  
	   The	  aim	  of	  the	  present	  report	  is	  to	  systematically	  review	  the	  cases	  of	  
altered	  mental	  status	  or	  epileptic	  seizures	  that	  result	  from	  dilutional	  




	   Between	  August	  and	  October	  2012	  we	  performed	  a	  thorough	  computer-­‐based	  
search	  of	  the	  terms	  “desmopressin	  hyponatr[a]emia	  enuresis",	  “DDAVP	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hyponatr[a]emia	  enuresis”,	  “desmopressin	  hyponatr[a]emia	  bedwetting”	  and	  
“DDAVP	  hyponatr[a]emia	  bedwetting”	  in	  the	  U.S.	  National	  Library	  of	  Medicine	  
database.	  For	  this	  purpose	  we	  used	  the	  principles	  underlying	  the	  UK	  Economic	  
and	  Social	  Research	  Council	  guidance	  on	  the	  conduct	  of	  narrative	  synthesis	  
and	  the	  Preferred	  Reporting	  Items	  for	  Systematic	  Reviews	  and	  Meta-­‐Analyses	  
statement	  [5].	  We	  retained	  for	  the	  final	  analysis	  exclusively	  reports	  
available	  as	  a	  full-­‐length	  article	  or	  as	  a	  letter,	  which	  included	  
individually	  described	  cases	  of	  epileptic	  seizures	  or	  altered	  mental	  status	  
caused	  by	  hyponatremia	  associated	  with	  the	  use	  of	  desmopressin	  in	  enuretic	  
subjects.	  Reports	  commenting	  the	  aforementioned	  cases	  and	  studies	  addressing	  
the	  possible	  mechanisms	  underlying	  the	  tendency	  towards	  severe	  signs	  of	  
hyponatremia	  were	  also	  retained.	  Pertinent	  secondary	  references	  found	  in	  the	  
articles	  were	  also	  considered.	  Reports	  published	  in	  languages	  other	  than	  
English,	  French,	  German,	  Italian,	  Portuguese,	  or	  Spanish	  were	  excluded.	  If	  
the	  same	  case	  was	  present	  in	  different	  publications,	  we	  retained	  exclusively	  
the	  most	  complete	  description.	  From	  each	  report	  dealing	  with	  severe	  signs	  of	  
hyponatremia	  in	  subjects	  with	  enuresis	  managed	  with	  desmopressin,	  two	  of	  us	  
(BL	  and	  MGB)	  independently	  excerpted	  data	  on	  gender;	  age;	  dosage	  and	  mode	  of	  
administration	  of	  desmopressin;	  further	  identifiable	  factors	  predisposing	  to	  
hyponatremia;	  clinical	  presentation;	  blood	  sodium	  concentration;	  and	  clinical	  
course.	  
	   Descriptive	  statistics	  are	  presented	  as	  median	  and	  interquartile	  range	  or	  
as	  relative	  frequency,	  as	  appropriate.	  The	  two-­‐sided	  Wilcoxon-­‐Mann-­‐Whitney	  
test	  for	  two	  independent	  samples	  and	  the	  two-­‐sided	  Fisher	  exact	  test	  were	  
performed	  for	  analysis.	  Significance	  was	  assumed	  when	  P<0.05.	  
	  
Search	  results	  
	   The	  flowchart	  of	  the	  literature	  search	  process	  (figure	  1)	  indicates	  that	  
the	  initial	  search	  revealed	  164	  publications,	  of	  which	  115	  remained	  after	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excluding	  duplicates	  (ie,	  publications	  found	  with	  two	  or	  more	  search	  terms).	  
Eighty	  of	  them	  were	  reviewed	  in	  detail	  and	  31	  were	  retained	  for	  the	  final	  
analysis.	  Five	  pertinent	  reports	  were	  found	  in	  the	  references	  of	  the	  
mentioned	  31	  reports.	  Hence,	  a	  total	  of	  36	  reports	  were	  included	  in	  the	  final	  
analysis	  [6-­‐40]:	  31	  in	  English	  [6-­‐36]	  and	  5	  in	  French	  [37-­‐41].	  They	  had	  been	  
reported	  from	  the	  following	  countries:	  United	  States	  of	  America	  (N=7),	  Great	  
Britain	  (N=6),	  France	  (N=5),	  Belgium	  (N=3),	  Canada	  (N=3),	  Denmark	  (N=2),	  
Germany	  (N=2),	  Switzerland	  (N=2),	  Czech	  Republic	  (N=1),	  Finland	  (N=1),	  India	  
(N=1),	  Ireland	  (N=1),	  Israel	  (N=1),	  and	  South	  Africa	  (N=1).	  
	  
Results	  
Patients	  with	  severe	  signs	  of	  hyponatremia	  
	   Fitfy-­‐four	  cases	  of	  hyponatremia	  secondary	  to	  desmopressin	  treatment	  
presenting	  with	  severe	  signs	  were	  found	  in	  31	  reports	  [6-­‐29,	  37-­‐41].	  In	  
addition	  to	  desmopressin,	  three	  patients	  were	  on	  long-­‐term	  medication	  with	  
oxybutynin	  and	  two	  with	  imipramine.	  Severe	  signs	  of	  hyponatremia	  can	  occur	  at	  
any	  time	  after	  starting	  medication	  with	  desmopressin.	  In	  exactly	  half	  of	  the	  
cases	  where	  this	  could	  be	  determined,	  however,	  severe	  signs	  of	  hyponatremia	  
developed	  within	  14	  days.	  It	  is	  true,	  however,	  that	  in	  10	  percent	  of	  the	  
cases	  severe	  signs	  of	  hyponatremia	  occurred	  one	  year	  or	  more	  after	  starting	  
desmopressin.	  
	   The	  age	  of	  the	  54	  subjects	  ranged	  from	  2.0	  to	  37,	  median	  9.0	  years	  with	  a	  
male	  to	  female	  ratio	  of	  1.71	  (table	  1).	  At	  least	  31	  patients	  (57	  percent)	  
reported	  headache,	  nausea	  or	  vomiting	  before	  the	  onset	  of	  severe	  signs	  of	  
hyponatremia.	  As	  compared	  with	  8	  patients	  presenting	  exclusively	  with	  altered	  
mental	  status,	  46	  patients	  presenting	  with	  epileptic	  seizures	  had	  a	  
significantly	  lower	  blood	  sodium	  concentration	  (P<0.01)	  and	  were	  more	  
frequently	  male	  (P<0.05).	  An	  oral	  formulation	  (either	  a	  tablet	  or	  a	  
lyophilizate)	  had	  been	  used	  in	  7	  cases	  and	  the	  intranasal	  formulation	  (either	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droplets	  or	  a	  spray)	  had	  been	  used	  in	  the	  remaining	  47	  patients.	  Excess	  fluid	  
intake	  was	  documented	  as	  a	  contributing	  factor	  in	  at	  least	  22	  of	  the	  54	  cases	  
(41	  percent).	  Three	  further	  subjects	  (6	  percent)	  were	  concurrently	  managed	  
with	  desmopressin	  and	  oxybutynin.	  It	  is	  tempting	  to	  assume	  an	  excess	  fluid	  
intake	  in	  these	  patients	  due	  to	  oxybutynin-­‐induced	  dry	  mouth	  mucosa.	  Finally,	  
in	  6	  cases	  (11	  percent)	  severe	  signs	  of	  hyponatremia	  developed	  in	  the	  context	  
of	  intercurrent	  illnesses	  that	  predispose	  to	  fluid	  or	  electrolyte	  imbalance	  
(large	  fluid	  intake	  to	  maintain	  hydration	  is	  generally	  advised	  in	  these	  
common	  conditions).	  Patients	  with	  severe	  signs	  of	  hyponatremia	  on	  treatment	  
with	  nasal	  desmopressin	  and	  those	  on	  oral	  desmopressin	  did	  not	  significantly	  
(table	  2)	  differ	  with	  respect	  to	  median	  age,	  male	  to	  female	  ratio	  and	  
contributing	  factors	  (either	  excess	  fluid	  intake	  or	  an	  intercurrent	  illness).	  
However,	  blood	  sodium	  was	  lower	  on	  average	  by	  8	  mmol/L	  (P<0.02)	  in	  patients	  
treated	  with	  an	  intranasal	  desmopressin	  formulation.	  
	   No	  long-­‐term	  sequelae	  were	  reported	  with	  the	  exception	  of	  the	  case	  of	  a	  
27-­‐year-­‐old	  Irish	  man,	  an	  occasional	  heavy	  binge	  drinker	  treated	  for	  8	  years	  
with	  desmopressin	  nasal	  spray	  for	  enuresis	  [18].	  After	  consuming	  alcohol,	  he	  
developed	  seizures	  and	  subsequently	  fell	  off	  a	  chair	  injuring	  his	  head.	  He	  
was	  found	  to	  be	  deeply	  comatose	  with	  a	  Glasgow	  Coma	  Scale	  score	  of	  4/15	  and	  
with	  a	  blood	  sodium	  level	  of	  116	  mmol/L.	  Imaging	  studies	  disclosed	  a	  left	  
fronto-­‐temporal	  contusion	  with	  mass	  effect	  and	  a	  small	  subdural	  hematoma.	  
Despite	  careful	  correction	  of	  low	  sodium	  and	  appropriate	  management	  of	  head	  
injury,	  he	  developed	  severe	  cerebral	  edema	  and	  died	  [18].	  
Metabolism	  of	  desmopressin	  in	  subjects	  with	  tendency	  towards	  
hyponatremia	  
	   A	  Belgian	  group	  observed	  that	  some	  enuretic	  subjects	  managed	  with	  
intranasal	  desmopressin	  delay	  their	  first	  morning	  voiding	  until	  late	  in	  the	  
afternoon	  and	  sometimes	  present	  signs	  possibly	  consistent	  with	  hyponatremia	  
like	  headache,	  nausea	  or	  vomiting.	  As	  a	  consequence,	  these	  authors	  suspected	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the	  existence	  of	  a	  prolonged	  desmopressin	  bioactivity	  [30].	  In	  a	  group	  of	  
pediatric	  patients	  on	  intranasal	  desmopressin	  for	  enuresis,	  a	  prolonged	  
maximal	  urinary	  concentration	  capacity	  and	  a	  delayed	  restoration	  of	  daytime	  
diluting	  capacity	  were	  noted,	  thereby	  supporting	  the	  hypothesis	  of	  prolonged	  
desmopressin	  bioactivity	  [30].	  The	  intriguing	  report,	  which	  did	  not	  address	  
the	  bioactivity	  of	  desmopressin	  following	  oral	  administration,	  has	  been	  
widely	  debated	  [31-­‐33,	  35].	  
	  
Discussion	  
	   Vasopressin	  regulates	  blood	  sodium	  concentration	  through	  the	  control	  of	  
water	  excretion	  by	  the	  kidney	  and	  it	  exerts	  an	  antidiuretic	  effect	  that	  is	  
mediated	  by	  renal	  receptors	  [42].	  Vasopressin	  also	  has	  a	  vasopressor	  effect	  
that	  is	  mediated	  by	  vascular	  receptors	  [42].	  Desmopressin	  acetate	  is	  a	  
selective	  renal	  receptor	  agonist	  and	  it	  has	  no	  effect	  on	  vascular	  receptor:	  
as	  such,	  the	  drug	  retains	  the	  antidiuretic	  properties	  of	  vasopressin	  but	  it	  
avoids	  vasopressor	  effects.	  The	  most	  important	  current	  indication	  for	  
desmopressin,	  which	  was	  originally	  developed	  for	  the	  management	  of	  central	  
diabetes	  insipidus,	  is	  enuresis.	  For	  enuresis,	  desmopressin	  is	  available	  as	  
nasal	  spray	  (administered	  in	  doses	  of	  10	  to	  40	  μg	  nightly),	  oral	  tablets,	  and	  
a	  rapidly	  melting	  oral	  lyophilisate	  (both	  administered	  in	  doses	  of	  100	  to	  400	  
µg	  nightly).	  It	  is	  logical	  to	  assume	  that	  the	  reason	  for	  antienuretic	  effect	  
of	  desmopressin	  is	  reduced	  urine	  production	  [1-­‐4].	  There	  is,	  however,	  also	  
some	  evidence	  that	  central	  nervous	  system	  effects	  may	  be	  active	  as	  well	  [2-­‐
4].	  
	   Desmopressin	  is	  generally	  considered	  a	  safe	  drug	  for	  enuresis	  and	  has	  been	  
prescribed	  in	  many	  millions	  of	  cases	  [1-­‐4].	  The	  purpose	  of	  our	  systematic	  
review	  of	  the	  literature	  was	  not	  to	  provide	  an	  overview	  of	  desmopressin	  
tolerability,	  but	  rather	  to	  investigate	  the	  very	  rare	  cases	  that	  present	  with	  
severe	  symptoms	  of	  hyponatremia	  secondary	  to	  desmopressin	  treatment	  for	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enuresis.	  In	  enuresis	  managed	  with	  desmopressin,	  dilutional	  hyponatremia	  may	  
develop	  following	  excess	  fluid	  intake,	  during	  intercurrent	  illnesses	  that	  
might	  otherwise	  affect	  fluid	  balance	  or	  in	  case	  of	  prolonged	  desmopressin	  
bioactivity	  [43].	  The	  present	  report	  indicates	  that	  excessive	  fluid	  intake	  
and	  intercurrent	  clinical	  illnesses	  that	  might	  otherwise	  affect	  fluid	  balance	  
very	  often	  precede	  severe	  hyponatremic	  encephalopathy	  in	  subjects	  with	  
enuresis	  on	  either	  nasal	  or	  oral	  desmopressin.	  An	  increased	  bioactivity	  of	  
desmopressin	  can	  be	  caused	  by	  an	  excessive	  absorption	  through	  the	  nasal	  
mucosa,	  since	  both	  allergic	  and	  inflamed	  airways	  significantly	  change	  the	  
bioavailability	  of	  nasally	  administered	  desmopressin	  [2-­‐4,	  43].	  Finally,	  a	  
prolonged	  duration	  of	  action	  with	  conventional	  doses	  of	  intranasal	  
desmopressin	  has	  been	  documented	  in	  a	  small	  group	  of	  enuretic	  subjects	  [30].	  
	   More	  than	  85	  percent	  of	  the	  reported	  subjects	  who	  developed	  severe	  
hyponatremic	  encephalopathy	  were	  on	  nasal	  desmopressin,	  suggesting	  that	  the	  
oral	  formulation	  is	  safer	  [44].	  An	  alternative	  possibility	  to	  account	  for	  the	  
smaller	  number	  of	  case	  reports	  with	  the	  oral	  formulation	  is	  that	  the	  medical	  
community	  has	  presumed	  that	  the	  literature	  contains	  a	  sufficient	  number	  of	  
case	  reports	  of	  hyponatremia	  associated	  with	  nasal	  desmopressin	  (prescribed	  
for	  enuresis	  since	  approximately	  1980)	  management	  and	  the	  occurrence	  with	  an	  
oral	  formulation	  (prescribed	  since	  1990)	  is	  no	  longer	  reportable.	  Another	  
possibility	  is	  that	  the	  oral	  formulations	  have	  been	  marketed	  for	  a	  shorter	  
period.	  Notwithstanding	  these	  possibilities,	  it	  is	  assumed	  that	  the	  oral	  
application	  harbors	  a	  safety	  profile	  superior	  to	  the	  intranasal	  route	  [2-­‐4,	  
44].	  In	  the	  present	  analysis,	  blood	  sodium	  was	  significantly	  lower	  in	  
patients	  treated	  with	  intranasal	  desmopressin,	  further	  supporting	  the	  
mentioned	  assumption.	  We	  think	  that	  administration	  of	  a	  higher	  than	  
recommended	  dose	  is	  more	  likely	  with	  an	  intranasal	  formulation:	  some	  patients	  
might	  feel	  unsure	  whether	  an	  adequate	  dose	  has	  been	  administered	  with	  an	  
intranasal	  formulation	  and	  they	  might	  increase	  the	  dose	  to	  compensate	  for	  
this	  uncertainty	  [2-­‐4,	  44].	  In	  fact,	  desmopressin	  intranasal	  formulations	  are	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no	  longer	  indicated	  for	  the	  treatment	  of	  enuresis.	  Furthermore,	  considering	  
that	  young	  age	  was	  identified	  as	  a	  risk	  factor	  for	  hyponatremia,	  desmopressin	  
is	  not	  recommended	  for	  enuretic	  children	  younger	  than	  6	  years	  [2-­‐4,	  44].	  
	  
Conclusions	  
	   Severe	  hyponatremic	  encephalopathy	  is	  a	  very	  rare	  but	  recognized	  
complication	  of	  management	  with	  desmopressin	  in	  subjects	  affected	  by	  
enuresis.	  This	  complication	  mostly	  develops	  14	  days	  or	  less	  after	  starting	  
the	  medication,	  following	  excess	  fluid	  intake,	  during	  intercurrent	  illnesses	  
and	  in	  subjects	  managed	  with	  the	  intranasal	  formulation.	  It	  is	  often	  preceded	  
by	  headache,	  nausea	  or	  vomiting	  that	  appear	  the	  morning	  and	  by	  a	  delayed	  
first	  morning	  voiding	  following	  desmopressin	  administration	  in	  the	  evening.	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Figure	  1-­‐	  Legend	  
Flowchart	  of	  the	  literature	  search	  process.	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   All	  cases	   Severely	  Altered	   Convulsions	   Significance	  
	   	   	   Mental	  Status	  
	  
N	   	   54	   8	   46	  
Desmopressin,	  nasal/oral	   47/7	   5/3	   42/4	   Not	  significant	  
	  
Gender,	  male/female	   34/20	   2/6	   32/14	   P<0.05	  
	  
Age,	  years	   9.0	  [6.5-­‐11]	   9.0	  [7.8-­‐19]	   9.0	  [6.0-­‐11]	   Not	  significant	  
Age	  ≤6.0	  years,	  N	   11	   1	   10	   Not	  significant	  
	  
Blood	  sodium	  level,	  mmol/L	   119	  [116-­‐122]	   124	  [120-­‐125]	   118	  [115-­‐121]	   P<0.01	  
	  
Contributing	  factor	  
	   Excess	  fluid	  intake,	  N	   25	   4	   21	  
	   Intercurrent	  illness,	  N	   6	   1	   5	  




The	  results	  are	  given	  either	  as	  median	  (with	  interquartile	  range	  between	  brackets)	  or	  as	  relative	  frequency.	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Table	  2:	  Clinical	  and	  laboratory	  data	  in	  subjects	  with	  severe	  signs	  of	  hyponatremia	  secondary	  to	  either	  nasal	  or	  oral	  




	   	   Oral	  Desmopressin	   Nasal	  Desmopressin	   Significance	  
	  
	  
N	   	   7	   47	  
	  
Age,	  years	   9.0	  [6.5-­‐10]	   9.4	  [6.5-­‐12]	   Not	  significant	  
	  
Gender,	  male/female	   4/3	   30/17	   Not	  significant	  
	  
Altered	  mental	  status/convulsions	   3/4	   5/42	  
	  
Blood	  sodium	  level,	  mmol/L	   124	  [122-­‐126]	   116	  [118-­‐121]	   P<0.02	  
	  
Contributing	  factors	  
	   Excess	  fluid	  intake,	  N	   5	   25	  
	   Intercurrent	  illness,	  N	   1	   5	  




The	  results	  are	  given	  either	  as	  median	  (with	  interquartile	  range	  between	  brackets)	  or	  as	  relative	  frequency.	  
	  
	  
